Literature DB >> 20101800

Transitions of multifocal electroretinography in patients with age-related macular degeneration after combination therapy with photodynamic therapy and intravitreal bevacizumab.

Yan Liu1, Feng Wen, Jiaqing Li, Chengguo Zuo, Meng Li.   

Abstract

To compare the differences in color Doppler imaging (CDI) and pattern visual evoked potential (P-VEP) examinations between normal tension glaucoma (NTG) and hypertension primary open angle glaucoma (HTG) patients, and investigate the relation between flow velocities measured by CDI and P-VEP examination in NTG and HTG patients. Sixty NTG patients, 66 HTG patients and 44 control subjects underwent CDI evaluation of the ophthalmic artery (OA), short posterior ciliary artery (SPCA) and central retinal arteries (CRA). The peak systolic velocities (PSV) and end-diastolic velocities (EDV) and resistive index (RI) of all retrobulbar vessels were measured. The latency and amplitude of P100 in P-VEP were recorded from the three groups. The differences of CDI and P-VEP parameters among NTG group, HTG group and control group were compared by one-way analysis of variance. The correlations between CDI parameters and visual field indices, P-VEP and visual field indices, P-VEP and CDI parameters in NTG and HTG patients were evaluated by Pearson's correlation analysis. NTG and HTG patients had the lower EDV and higher RI in the OA, CRA and SPCA comparing with that of control subjects. NTG and HTG patients also had lower PSV in OA and CRA comparing with that of control subjects. There was no significant difference in the blood flow velocities and RI of all retrobulbar vessels between NTG and HTG patients. The latency of P100 in VEP delayed and the amplitude of P100 decreased in the NTG and HTG patients comparing with that of the control group. There was no significant difference in the latency and amplitude of P100 between the NTG and HTG patients. The RI of OA and SPCA were negatively correlated with the mean deviation (MD) values in the NTG and HTG patients. The RI of OA was positively correlated with the PSD value in the NTG and HTG patients. The MD values in the NTG and HTG patients were negatively correlated with the latency time of P100. The RI of OA was positively correlated with the latency time of P100 in NTG and HTG patients. The RI of OA was negatively correlated with the amplitude of P100 in HTG patients. No significant difference was found in the parameters of CDI and P-VEP between NTG and HTG patients. The certain parameters of CDI were correlated with P-VEP parameters in NTG and HTG patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20101800     DOI: 10.1007/s10633-009-9189-2

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  20 in total

1.  Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.

Authors:  Ioannis D Ladas; Athanasios I Kotsolis; Thanos D Papakostas; Alexandros A Rouvas; Dimitrios A Karagiannis; Ioannis Vergados
Journal:  Retina       Date:  2007-09       Impact factor: 4.256

2.  Different transitions of multifocal electroretinogram recordings between patients with age-related macular degeneration and polypoidal choroidal vasculopathy after photodynamic therapy.

Authors:  H Imai; S Honda; Y Nakanishi; H Yamamoto; Y Tsukahara; A Negi
Journal:  Br J Ophthalmol       Date:  2006-07-06       Impact factor: 4.638

3.  The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study.

Authors:  R Klein; B E Klein; S C Jensen; S M Meuer
Journal:  Ophthalmology       Date:  1997-01       Impact factor: 12.079

4.  Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).

Authors:  Rogério A Costa; Rodrigo Jorge; Daniela Calucci; Luiz A S Melo; José A Cardillo; Ingrid U Scott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-02-28       Impact factor: 3.117

5.  Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8.

Authors:  Peter K Kaiser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

6.  A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.

Authors:  L Arias; J M Caminal; L Casas; C Masuet; M B Badia; M Rubio; O Pujol; J Arruga
Journal:  Br J Ophthalmol       Date:  2008-09-09       Impact factor: 4.638

7.  Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.

Authors:  Mi In Roh; Hong Suk Kim; Ji Hun Song; Jong Baek Lim; Oh Woong Kwon
Journal:  Ophthalmology       Date:  2009-01       Impact factor: 12.079

8.  Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study.

Authors:  Marilita M Moschos; Michael Moschos
Journal:  Doc Ophthalmol       Date:  2008-01-10       Impact factor: 2.379

9.  Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.

Authors:  Ratimir Lazic; Nikica Gabric
Journal:  Ophthalmology       Date:  2007-06       Impact factor: 12.079

10.  ISCEV guidelines for clinical multifocal electroretinography (2007 edition).

Authors:  Donald C Hood; Michael Bach; Mitchell Brigell; David Keating; Mineo Kondo; Jonathan S Lyons; Anja M Palmowski-Wolfe
Journal:  Doc Ophthalmol       Date:  2007-10-31       Impact factor: 2.379

View more
  2 in total

1.  Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor.

Authors:  Yukio Sassa; Yasuaki Hata
Journal:  Clin Ophthalmol       Date:  2010-04-26

2.  Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration.

Authors:  Pasi Vottonen; Kai Kaarniranta; Ari Pääkkönen; Ina M Tarkka
Journal:  Clin Ophthalmol       Date:  2013-02-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.